How should investors diversify their portfolios

How should investors diversify their portfolios ETFMaticHow should investors diversify their portfolios

How should investors diversify their portfolios
Robin Powell

Prof Martin Weber – University of Mannheim

Hello There! One of the most important lessons we’ve learned from more than 60 years of portfolio construction is that diversifying your investments is a very good idea.

Professor Martin Weber from the University of Mannheim is a recognised international authority on the subject. He says, every portfolio requires a degree of balance:

Diversifying is the key thing to investment. There is a big saying: diversification is the only free lunch you get or you hate risks and you can destroy risk by diversification. That’s the reason it is so important.

The next question is: How do you diversify? The important thing, says Professor Weber, is to diversify across different geographical regions and different asset classes.

The idea of optimally diversifying is that you look at different asset classes first and you diversify across different asset classes and as the second thing, even within these asset classes, you diversify as broad as possible. If you think about different asset classes, clearly as stock, bond and commodities – you can think about other ones – but these are the most liquid tradable asset classes.

Within the stock, you have a variety of different stocks.

Of course, the downside of diversification is that you aren’t heavily exposed to the sector that’s about to enjoy big returns.

But that’s not the point. After all, nobody knows which region or asset class is about to outperform from one year to the next. The beauty of the idea of diversifying is, that you always have some bad things and some good things happening: There might be a bond bubble, there might be a gold rush, there might be a lot of things going on. That is basically the idea of diversifying. If you use a passive diversified strategy, you don’t have to care. It doesn’t matter to you.

Most investors should primarily hold stocks, as well as bonds to dampen the risk. But Professor Weber also recommends keeping a cash reserve, for two reasons.

It’s basically an idea to reduce risk. That’s one reason why you should hold cash in accordance with your risk preference. The second reason is that it is a buffer in case you need some money because your car breaks down, you want to go for a big journey or remodel the house. That’s a different need of cash. So for those two different reasons you might want to hold cash.

So that, in a nutshell, is diversification. It’s not complicated, but it’s very sensible. After all, as an investor, it’s better to be roughly right than completely wrong. Thank you to Professor Weber, and to you for watching. Goodbye.


With all investments your capital is at risk and the value of your investments and the income deriving from it can rise as well as fall. Past performance is not a guide to future performance. This site is provided for information purposes only and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any financial instruments. Robo-advisor is category established by U.S. companies like Betterment and Wealthfront, it does not imply we provide advice. Ask a Financial Advisor if in doubt. Amazon, Amundi, Apple, Barclays, Blackrock, Boost, Deutsche Bank, ETF Securities, First Trust, Google, HSBC, Invesco, Lyxor, SaxoBank, State Steet, Source, UBS, Ubuntu, Vanguard, Windows and Wisdom Tree are trademarks of their respective owners. ETFmatic Ltd is authorised and regulated by the Financial Conduct Authority (No. 657261) and is a limited liability company registered in England and Wales, no. 08856747, with a registered office at 4th Floor 7-10 Chandos Street, Cavendish Square, W1G 9DQ, London, United Kingdom. ETFmatic Ltd is registered for VAT with the HMRC with registration number 190 8981 63. The custodian of our clients money is Barclays Bank, while the ETF´s are held by Saxo Bank in a segregated account on the name of ETFmatic Global Nominee Ltd. Our services are available in Austria, Belgium, Denmark, Estonia, Finland, France, Germany, Ireland, Italy, Latvia, Netherlands, Norway, Poland, Portugal, Spain, Sweden and the United Kingdom. Free simulation accounts are available worldwide.

An ETF that invest in Immunotherapy

An ETF that invest in Immunotherapy

Loncar Cancer Immunotherapy ETF (CNCR), An ETF that invest in Immunotherapy

ABOUT THE FUND

The Loncar Cancer Immunotherapy ETF, An ETF that invest in Immunotherapy, seeks to track the LCINDX index. It is made up of a basket of companies that develop therapies to treat cancer by harnessing the body’s own immune system. Immunotherapy is a transformational field within the biotechnology space that is expected to become the foundational treatment for cancer over the next ten years. A sector ETF focusing on a unique technology like cancer immunotherapy allows investors to focus on interest areas more precisely than broad indices. LCINDX is an equal-weighted index containing both large pharmaceutical and growth-oriented biotechnology companies that are leading in this approach.

Click to enlarge

INVESTMENT RATIONALE

Cancer immunotherapy has become an important sector in the biotechnology space and is changing the way many cancers are treated. While traditional medicines like chemotherapies often give cancer a broad punch, the benefit of using immunotherapy is derived from the immune system’s dynamic nature and the way it can more precisely be tailored to fight a patient’s disease. Some immunotherapies have exhibited uncommon results in clinical trials.

Today, many new classes of cancer immunotherapies are being developed. These include checkpoint inhibitors (which are already FDA approved for melanoma and lung cancer), cancer vaccines, bispecific antibodies, and chimeric antigen receptor (CAR-T) technologies. With this distinct sector focus, the fund aims to help investors capture a growth area of the biotechnology space. At the same time, it will support this method of treating cancer by providing capital to public companies that are leaders in the space.

Click to enlarge

* Fund holdings and allocations are subject to change at any time and should not be interpreted as an offer of these securites.

INDEX PROVIDER

Loncar Investments LLC was founded by noted independent biotech investor and analyst Brad Loncar. Mr. Loncar regularly provides his unique insight and analysis on this market segment to the investment community via a variety of publishing platforms. Through Loncar Investments LLC, Mr. Loncar incorporates his extensive research into biotech companies and technologies to develop indexes focused on precise investment opportunities.

Click to enlarge

Disclaimer

The Fund’s investment objectives, risks, charges and expenses must be considered carefully before investing. The summary and statutory prospectuses contain this and other important information about the investment company, and it may be obtained by calling 800-617-0004. Read it carefully before investing. Investing involves risk, including the possible loss of principal. Shares of any ETF are bought and sold at market price (not NAV), may trade at a discount or premium to NAV and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. The Fund will invest in immunotherapy companies which are highly dependent on the development, procurement and marketing of drugs and the protection and exploitation of intellectual property rights. A company’s valuation can also be greatly affected if one of its products is proven or alleged to be unsafe, ineffective or unprofitable. The costs associated with developing new drugs can be significant, and the results are unpredictable. The process for obtaining regulatory approval by the U.S. Food and Drug Administration or other governmental regulatory authorities is long and costly and there can be no assurance that the necessary approvals with be obtained and maintained.

The Fund may invest in foreign securities, which involve political, economic, currency risk, greater volatility, and differences in accounting methods. The Fund is non-diversified meaning it may concentrate its assets in fewer individual holdings than a diversified fund. Therefore, the Fund is more exposed to individual stock volatility than a diversified fund. The Fund invests in smaller companies, which may have more limited liquidity and greater volatility compared to larger companies. The Fund is not actively managed and may be affected by a general decline in market segments related to the index. The fund invests in securities included in, or representative of securities included in, the index, regardless of their investment merits. The performance of the fund may diverge from that of the Index and may experience tracking error to a greater extent than a fund that seeks to replicate an index.

The Loncar Cancer Immunotherapy ETF, An ETF that invest in Immunotherapy, is distributed by Quasar Distributors, LLC. Loncar Investments is the index provider of the Fund. INDXX, LLC helps Loncar with risk management and index construction.